Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 March 2018Website:
http://www.q32bio.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 25 Oct 2024 20:26:48 GMTDividend
Analysts recommendations
Institutional Ownership
QTTB Latest News
The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.
What type of business is Q32 Bio?
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
What sector is Q32 Bio in?
Q32 Bio is in the Healthcare sector
What industry is Q32 Bio in?
Q32 Bio is in the Biotechnology industry
What country is Q32 Bio from?
Q32 Bio is headquartered in United States
When did Q32 Bio go public?
Q32 Bio initial public offering (IPO) was on 28 March 2018
What is Q32 Bio website?
https://www.q32bio.com
Is Q32 Bio in the S&P 500?
No, Q32 Bio is not included in the S&P 500 index
Is Q32 Bio in the NASDAQ 100?
No, Q32 Bio is not included in the NASDAQ 100 index
Is Q32 Bio in the Dow Jones?
No, Q32 Bio is not included in the Dow Jones index
When was Q32 Bio the previous earnings report?
No data
When does Q32 Bio earnings report?
The next expected earnings date for Q32 Bio is 29 November 2024